Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

2XA8

Crystal structure of the Fab domain of omalizumab at 2.41A

Summary for 2XA8
Entry DOI10.2210/pdb2xa8/pdb
DescriptorOMALIZUMAB HEAVY CHAIN, OMALIZUMAB LIGHT CHAIN (3 entities in total)
Functional Keywordsxolair, allergy, immune system
Biological sourceHOMO SAPIENS (HUMAN)
More
Total number of polymer chains2
Total formula weight47220.26
Authors
Huang, C.H.,Hung, F.H.A.,Lim, C.,Chang, T.W.,Ma, C. (deposition date: 2010-03-30, release date: 2011-05-11, Last modification date: 2024-10-16)
Primary citationWright, J.D.,Chu, H.M.,Huang, C.H.,Ma, C.,Chang, T.W.,Lim, C.
Structural and Physical Basis for Anti-IgE Therapy.
Sci Rep, 5:11581-11581, 2015
Cited by
PubMed Abstract: Omalizumab, an anti-IgE antibody, used to treat severe allergic asthma and chronic idiopathic urticaria, binds to IgE in blood or membrane-bound on B lymphocytes but not to IgE bound to its high (FcεRI) or low (CD23) affinity receptor. Mutagenesis studies indicate overlapping FcεRI and omalizumab-binding sites in the Cε3 domain, but crystallographic studies show FcεRI and CD23-binding sites that are far apart, so how can omalizumab block IgE from binding both receptors? We report a 2.42-Å omalizumab-Fab structure, a docked IgE-Fc/omalizumab-Fab structure consistent with available experimental data, and the free energy contributions of IgE residues to binding omalizumab, CD23, and FcεRI. These results provide a structural and physical basis as to why omalizumab cannot bind receptor-bound IgE and why omalizumab-bound IgE cannot bind to CD23/FcεRI. They reveal the key IgE residues and their roles in binding omalizumab, CD23, and FcεRI.
PubMed: 26113483
DOI: 10.1038/srep11581
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.42 Å)
Structure validation

226707

건을2024-10-30부터공개중

PDB statisticsPDBj update infoContact PDBjnumon